Stock DNA
Miscellaneous Commercial Services
PLN 94 Million (Micro Cap)
49.00
NA
0.00%
0.57
23.44%
11.38
Revenue and Profits:
Net Sales:
0 Million
(Quarterly Results - Mar 2025)
Net Profit:
0 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-34.65%
0%
-34.65%
6 Months
-16.85%
0%
-16.85%
1 Year
-16.25%
0%
-16.25%
2 Years
-59.93%
0%
-59.93%
3 Years
-75.58%
0%
-75.58%
4 Years
-89.06%
0%
-89.06%
5 Years
-8.66%
0%
-8.66%
Inno Gene SA for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
19.57%
EBIT Growth (5y)
27.35%
EBIT to Interest (avg)
2.94
Debt to EBITDA (avg)
0.54
Net Debt to Equity (avg)
0.76
Sales to Capital Employed (avg)
0.69
Tax Ratio
0.09%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
70.37%
ROE (avg)
58.07%
Valuation key factors
Factor
Value
P/E Ratio
49
Industry P/E
Price to Book Value
11.38
EV to EBIT
49.65
EV to EBITDA
49.15
EV to Capital Employed
7.61
EV to Sales
29.90
PEG Ratio
0.40
Dividend Yield
NA
ROCE (Latest)
15.33%
ROE (Latest)
23.44%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
No Trend
Mildly Bearish
Shareholding Snapshot : Jun 2023
Shareholding Compare (%holding) 
Majority shareholders
Non Institution
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 0 Foreign Institutions (0%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Mar'25 - QoQ
Mar'25
Dec'24
Change(%)
Net Sales
0.10
3.10
-96.77%
Operating Profit (PBDIT) excl Other Income
-0.00
3.00
-100.00%
Interest
0.00
0.00
Exceptional Items
-0.00
0.00
Consolidate Net Profit
-0.10
2.90
-103.45%
Operating Profit Margin (Excl OI)
-873.20%
957.90%
-183.11%
USD in Million.
Net Sales
QoQ Growth in quarter ended Mar 2025 is -96.77% vs 3,000.00% in Dec 2024
Consolidated Net Profit
QoQ Growth in quarter ended Mar 2025 is -103.45% vs 1,066.67% in Dec 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
3.30
1.10
200.00%
Operating Profit (PBDIT) excl Other Income
2.10
-2.90
172.41%
Interest
0.00
0.00
Exceptional Items
0.00
-1.30
100.00%
Consolidate Net Profit
1.90
-6.20
130.65%
Operating Profit Margin (Excl OI)
637.30%
-2,676.40%
331.37%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 200.00% vs -93.29% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 130.65% vs -2,166.67% in Dec 2023
About Inno Gene SA 
Inno Gene SA
Miscellaneous Commercial Services
Inno-Gene SA is a Poland-based holding company engaged in management of a portfolio of companies active in life-science sector through the technology, research and development. Inno-Gene SA’s portfolio comprises of Centrum Badan DNA Sp. z o.o., a company that provides services in the field of genetic medical diagnostics, including microbiological diagnosis of infection and the suitability of human congenital diseases using tests performed on DNA microarray technology. On March 22, 2013, the Company established a new subsidiary, Centrum Edukacji Bio-Medycznej Sp. z o.o. On April 11, 2013, the Company established two new indirect subsidiaries, Genomix Sp. z o.o. and Madgenetix Sp. z o.o. In addition, it operates through VitainSillica Sp z o o.
Company Coordinates 
Company Details
Ul. Sciegiennego 20 , POZNAN None : 60-128
Registrar Details






